THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) In its report, Hathi Committee had taken into account recommendations of the Wanchoo Committee.

(c) to (f) While increase in MAPE under DPCO, 1987, is based on the measures announced in 1986, the trade commission was increased in view of the increase in MAPE available to the industry. The existing trade commission is based on the recommendations made by the Committee constituted under the Chairmanship of the then Chairman, BICP.

(g) and (h) The details of the study by Reserve Bank of India are being collected and will be placed on the Table of the House.

बड़ी उर्वरक परियोजनाएं

1667. **सरदार जगजीत सिंह अरोड़ा :**
श्री वी० नारायणसामी :

क्या **प्रधान मंत्री** यह बताने की कृपा करेंगे कि :

(क) क्या सरकार का ध्यान 23 अगस्त, 1991 को "दि हिन्दुस्तान टाइम्स" "रैड टेप होल्डस अप थ्री मेगा फर्टिलाइजर प्रोजेक्ट्स" शीर्षक के अंतर्गत प्रकाशित समाचार की ओर दिलाया गया है ;

(ख) यदि हां, तो ये तीन बड़ी उर्वरक परियोजनाएं किन-किन स्थानों पर शुरु की जानी थीं, प्रत्येक की उत्पादन-क्षमता और स्थापना-लागत कितनी कितनी थी और प्रत्येक परियोजना को कब से उत्पादन शुरु कर देना था ;

(ग) क्या यह भी सच है कि इन तीनों संयंत्रों को निर्दिष्ट अवधि के भीतर स्थापित नहीं किया है ; और

(घ) यदि हां, तो उसके क्या कारण हैं और उनका निर्माण कार्य पूरा करने के लिए निर्धारित नई समयावधि कितनी है ;

रसायन और उर्वरक मंत्रालय में राज्य मंत्री (श्री चिन्ता मोहन) : (क) और (ग) जी, हां।

(ख) और (घ) गैस पर आधारित तीन उर्वरक परियोजनाएं राजस्थान में गड़ेपन तथा उत्तर-प्रदेश में बबराला और शाहजहांपुर में स्थित हैं, जिनकी स्थापित क्षमता क्रमश: 2250, 2250 और 2200 टन प्रति दिन यूरिया उत्पादित करने की है।

ये परियोजनाएं मुलत: गड़ेपन के मामले 1–1–90 से तथा बबराला उर्वरक परियोजना के मामले में 10–11–89 से 36 महीनों के अन्दर पूर्ण होनी निश्चित थीं। शाहजहांपुर परियोजना के लिए कोई शून्य तारीख घोषित नहीं की गयी है। इन परियोजनाओं के पूर्ण होने में विलम्ब हुआ है क्योंकि कुछ मंजूरियों अभी भी प्रतीक्षित हैं। इन परियोजनाओं के अब 1993/1994 में पूर्ण होने की संभावना है।

Names of Drugs recommended by BICP

1668. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1647 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) what are the names of drugs for which Government have received recommendations from BICP during the last three years;

(b) what are the names of drugs in respect of which BICP recommendations are yet to be decided upon by Government;

(c) whether it is a fact that Government have reduced the prices of certain drugs;

(d) if so, what are the names of such drugs and what was the price notified earlier and reduced later on;

(e) whether it is a fact that Government have found tailoring and loading in certain reports of costing by BICP; and

(f) if so. the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) The prices of bulk drugs are fixed by this Ministry on the basis of cost-cum-technical study conducted by BICP and their examination in this Department. Government has received several reports from BICP in connection with cost-cum-technical study of bulk drugs and the prices have been fixed after examination of report of BICP which have been notified in the Gazette of India from time to time. The BICP reports are input for our decision making in the process of price fixation. These reports are confidential in nature. In regard to other details asked for, the information is too voluminous and the time and efforts required for compiling the information will not be commensurate with the results likely to be achieved.

Representations of M.Ps. against the price decontrol of Glybenclamide

1669. SHRIMATI PRATIBHA SINGH: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1656 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) whether it is a fact that Government have received a number of representations from Members of Parliament against the price decontrol of Glybenclamide;

(b) if so, when each representation was received and what action has been taken on each;

(c) whether it is also a fact that sales turnover was one of the criteria of price decontrol;

(d) if so, what was the source of data of sales turnover and what are the basis of vertification of annual sales turnover of Glybenclamide;

(e) whether it is a fact that formulations of Glybenclamide has a monopoly of one company; and

(f) if so, names of the company and what is the market share enjoyed by that company?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) All such representations as have been received from Members of Parliament against the price decontrol of Glybenclamide has been considered by the Standing Committee. The matter is now under examination of the Government.

(c) Yes, Sir.

(d) The decontrol of bulk drug Glybenclamide is not based on sales turnover. The basis on which this drug has been price decontrolled is contained in the supplementary report of the Kelkar Committee, copy of which is available in the Parliament Library.

(e) and (f) M/s. Hoechst India Limited are the major formulator of bulk drug Glybenclamide. Market share of companies with regard to formulations are not monitored.

Procedures adopted by BICP

1670. KUMARI SAYEEDA KHATUN: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1654 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) what is the procedure adopted by BICP to work out the prices of formulations;

(b) what is the period taken after the notification/fixation of prices of bulk drugs;

(c) what are the names of drugs based on which prices of finished medicines have not been notified within three months of the fixation of prices of bulk drugs;

(d) whether implementation of the notified prices can be held in abeyance on the ground that it requires some clarifications;